Design, synthesis and antimicrobial activities of some novel 1,3,4-thiadiazole, 1,2,4-triazole-5-thione and 1,3-thiazolan-4-one derivatives of benzimidazole  by Barot, Kuldipsinh P. et al.
Journal of Saudi Chemical Society (2017) 21, S35–S43King Saud University
Journal of Saudi Chemical Society
www.ksu.edu.sa
www.sciencedirect.comORIGINAL ARTICLEDesign, synthesis and antimicrobial activities of
some novel 1,3,4-thiadiazole, 1,2,4-triazole-5-thione
and 1,3-thiazolan-4-one derivatives of
benzimidazole* Corresponding author.
E-mail addresses: barotkuldip@gmail.com (K.P. Barot),
11ftphdp9@nirmauni.ac.in (M.D. Ghate).
Peer review under responsibility of King Saud University.
Production and hosting by Elsevier
http://dx.doi.org/10.1016/j.jscs.2013.09.010
1319-6103 ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Kuldipsinh P. Barot a, Kuntal S. Manna b, Manjunath D. Ghate a,*a Department of Pharmaceutical Chemistry, Institute of Pharmacy, Nirma University, Ahmedabad 382 481, Gujarat, India
b Department of Pharmacy, Tripura University (A Central University), Suryamaninagar, Agartala 799 022, Tripura, IndiaReceived 2 July 2013; revised 25 September 2013; accepted 26 September 2013
Available online 8 October 2013KEYWORDS
Benzimidazole;
1,3,4-Thiadiazole;
1,2,4-Triazole-5-thione;
1,3-Thiazolan-4-one;
Structure–activity relation-
ship study;
Antimicrobial activityAbstract A series of novel 1,3,4-thiadiazole; 1,2,4-triazole-5-thione and 1,3-thiazolan-4-one deriv-
atives of benzimidazole were synthesized by nucleophilic substitution reaction of 2-substituted-1[H]
benzimidazole. Compounds (1H-benzo[d]imidazol-2-yl)methanamine 3, 2-(isothiocyanatomethyl)-
1H-benzo[d]imidazole 4, 4-(1H-benzo[d]imidazol-2-yl)benzenamine 6 and 4-(1H-benzo[d]imidazol-
2-yl)benzenamine 7 are synthesized for the synthesis of targeted compounds. Structures of all the
targeted synthesized compounds were evaluated by spectral and elemental methods of analysis.
All the synthesized compounds were evaluated for antibacterial and antifungal activities. Some
of the synthesized compounds showed good antibacterial and antifungal activities with 2.0 and
2.5 lg/mL MIC (minimum inhibitory concentration), respectively.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Discovery of new drugs for systemic opportunistic microbial
infections is a major challenge in infectious disease research.Microbial infections have increased in recent years, particu-
larly those that are of nosocomial origin, leading to a broad
use of agents with activity against pathogens [1]. Antimicrobial
resistance of different pathogens also became widespread [2].
Among the most common Gram-positive resistant pathogens
are Streptococcus pneumoniae, resistant to penicillin and mac-
rolides, methicillin-resistant Staphylococcus aureus (MRSA),
glycopeptides-intermediately resistant S. aureus (GISA), meth-
icillin-resistant Staphylococcus epidermidis, glycopeptide-resis-
tant enterococci and vancomycin-resistant enterococci (VRE)
[3]. The response of the pharmaceutical industry to this chal-
lenge was the development of new antibiotics active against
these pathogens [4]. Among these antibiotics, linezolid, an
S36 K.P. Barot et al.oxazolidinone; GAR-936, a tetracycline derivative; daptomy-
cin, a lipopeptide; and ortivancin (LY-333328), a glycopeptide
related to vancomycin are the novel antimicrobial agents [5].
Except for linezolid, which has been recently launched in many
countries, all other agents are still at various developmental
stages [6]. It is hoped that in the near future most of these
agents will be approved and thus the grim outlook of patients
infected with resistant Gram-positive bacteria, Gram-negative
and fungus may improve [7].
Promising new compounds have recently been identiﬁed in
an effort to supplement the relatively sparse portfolio of anti-
fungal drugs. Many of these compounds have deﬁned mecha-
nisms of action against fungal cells and have, in some cases,
aided the identiﬁcation of new selective targets in fungi [8].
For most of these compounds, however, factors such as a nar-
row spectrum of activity, susceptibility to efﬂux pumps, protein
binding, serum inactivation and poor pharmaceutical proper-
ties prevent their use in the clinic [9]. Even so, these compounds
are novel substrates for synthetic modiﬁcations that could lead
to the discovery of future antimicrobial drugs [10]. Corynecan-
din, Mer-WF3010, fusacandins and arthrichitin act as
inhibitors of cell wall biosynthesis. Sordarins, cispentacin and
azoxybacillin act as inhibitors of protein and amino acid
synthesis. Aureobacidin, rustmicin and khafrefungin act as
inhibitors of sphingolipid biosynthesis. UK2A and UK3A act
as inhibitors of electron transport. New therapies such as
addition of the iron chelator, deferasirox, in the treatment of
zygomycosis in diabetic patients, appear promising but
additional agents with new targets of action are urgently
needed [11].
The 1,3,4-thiadiazole; 1,2,4-triazoles-5-thione and 1,3-thia-
zolan-4-one nucleus has been incorporated into a wide variety
of therapeutically important agents, which mainly provides
antimicrobial activities [12]. Moreover, the chemistry of
1,3,4-thiadiazole; 1,2,4-triazoles-5-thione; 1,3-thiazolan-4-one
and their fused heterocyclic derivatives has shown potency to
their synthetic and effective biological importance [13]. For
example, a triazolothiadiazole system is a cyclic analog of
two very important components such as thiosemicarbazide
and biguanide, which often display antimicrobial, anticancer,
antitubercular, anti-inﬂammatory or anticonvulsant activities
[14]. In view of the above facts, in our present study, we have
synthesized different 1,3,4-thiadiazole; triazole-5-thione and
1,3-thiazolan-4-one derivatives as benzimidazole derivatives
for antimicrobial activities. These types of novel ring systems
have not been studied yet as antimicrobial activities against
multi-drug resistant microbial species [15,16].
2. Results and discussion
2.1. Chemistry
All the reagents were purchased from Sigma–Aldrich Chemi-
cals (Bangalore, India) and were used without further puriﬁca-
tion. All solvents were distilled and dried using dry sieves as
the usual manner. The moisture sensitive reactions were car-
ried out under nitrogen atmosphere. TLC analysis was carried
out on an aluminum foil pre-coated with silica gel 60 F254
(Sigma–Aldrich, Bangalore dealer). Melting points were deter-
mined on a Thomas micro hot stage apparatus and are uncor-
rected. Infrared spectra were determined as KBr solid disks+on a Shimadzu model 470 spectrophotometer. Mass spectra
were recorded on a JEOL JMS-600H instrument using electro
spray ionization (ESI) detector. 1H NMR spectra were re-
corded using a Jeol Eclipse 400 MHz spectrometer using
CDCl3 as NMR solvent and are reported in ppm down ﬁeld
from the residual CDCl3. Elemental analysis was performed
on a Elementar Vario Micro Cube analyzer and results were
within ±0.4% of the predicted values for all compounds. IR
(KBr) spectrum of all the synthesized compounds had strong
C‚C band at 1470–1575 cm1, which is similar as that of
the ordinary C‚C absorption (1400–1600 cm1). The forma-
tion of H-bond leads to an increase of their polarity, so the
strength of their double bond decreased and absorption moved
to lower wave number. The medium strong C–H band and
C–N band in IR spectra of all the compounds appeared at
3000–3050 cm1 and 1160–1350 cm1 respectively which is
similar as that of the ordinary C–H absorption (3000–
3100 cm1). The 1H NMR spectrum exhibited different signals
at different ppm which were assigned to the different types of
protons. 13C NMR showed various types of signals at different
ppm which were assigned for the different types of carbons of
all the target compounds. The synthetic routes leading to the
title compounds are summarized in schemes.
2-Aminomethyl-1[H] benzimidazole 3 was synthesized from
o-phenylenediamine 1 and glycine 2 when reﬂuxed with HCl
and water at 70–73 C [17]. Reaction of 2-methyl amino-1[H]
benzimidazole 3, dry pyridine and iodine at 0–5 C gave 2-
methylsulphonitrile-1[H]benzimidazole 4 when stirred for
3.5–4 h [18]. N-(4-(1H-benzo[d]imidazol-2-yl)methyl)-2-isoni-
cotinoyl hydrazine carbothioamide 9 was synthesized from 2-
methylsulphonitrile-1[H] benzimidazole 4 and isoniazide 8
[19]. N-(4-(1H-benzo[d] imidazol-2-yl) methyl)-5-(pyridin-4-
yl)-1, 3, 4-thiadiazol-2-amine 10 was synthesized from N-(4-
(1H-benzo[d] imidazol-2-yl) methyl)-2-isonicotinoyl hydrazine
carbothioamide 9 when reﬂuxed with 50 % H2SO4 [20]. (Z)-
2-(4-(1H-benzo[d] imidazol-2-yl) methylimino)-3-isonicotinoyl
thiazolidin-4-one 11 was synthesized from N-(4-(1H-benzo[d]
imidazol-2-yl) methyl)-2-isonicotinoyl hydrazine carbothioa-
mide 9 and chloroacetylchloride when reﬂuxed with chloroform
for 6 h [21]. 4-(4-(1H-benzo[d] imidazol-2-yl) methyl)-3-(pyri-
din-4-yl)-1H-1, 2, 4-triazole-5(4H)-thione 12 was synthesized
from N-(4-(1H-benzo[d] imidazol-2-yl) methyl)-2-isonicotinoyl
hydrazine carbothioamide 9 when reﬂuxed with HCl and
neutralization with NaOH [22] (Scheme 1). Physical
properties of 1,3,4-thiadiazole; triazole-5-thione and 1,3-thiazo-
lan-4-one derivatives of benzimidazole are summarized in
Table 1.
2.2. Antimicrobial activity
2.2.1. Antibacterial activity
Pharmacological evaluation is one of the most important
factors for the determination of activity of compounds. Evalu-
ation part of the work should be variable and easy to perform.
Since last few years, prevalence of infectious diseases has in-
creased to a great extent [23]. Antimicrobial agents are the
most commonly used to treat the different types of infectious
diseases. Synthesized compounds were evaluated for their anti-
bacterial activity against three Gram-positive organisms such
as Bacillus cereus (MTCC-430), Enterococcus faecalis
(MTCC-493), S. aureus (MTCC-737) and three Gram-negative
Scheme 1 Synthesis of 1,3,4-thiadiazole, triazole-5-thione and 1,3-thiazolan-4-one derivatives of benzomidazole.
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nas aeruginosa (MTCC-2642), Klebsiella pneumonia (MTCC-
109) [24]. Bacterial strains used were procured from Microbial
Type Culture Collection (MTCC), Institute of Microbial Tech-
nology (IMTECH), Chandigarh. Minimum inhibitory concen-
trations (MICs) were determined to evaluate the activity of
synthesized compounds against bacteria. Oﬂoxacin and metro-
nidazole were used as standard for antibacterial activity of the
synthesized compounds. It was found that the tested com-
pounds are more effective against the Gram-positive and
Gram-negative bacteria by comparing the antibacterial activity
of the synthesized compounds [25].
The minimum inhibitory concentration values (MICs)
against different Gram-positive and Gram-negative bacteria
were tested. The investigations showed signiﬁcant inhibitory
effects with the majority of the compounds with the MIC
values 5–18 lg/mL. The antibacterial data indicated that
N-((1H-benzo[d] imidazol-2-yl) methyl)-5-styryl-1, 3, 4-thia-
diazol-2-amine 24,2-(4-(1H-benzo[d] imidazol-2-yl) phenylimi-
no)-3-(2-phenylacetyl) thiazolidin-4-one 29 and 4-(4-(1H-benzo[d]imidazol-2-yl) phenyl)-3-benzyl-1H-1,2,4-triazole-5 (4H)-thi-
one 30 illustrated appreciable antibacterial activity (MIC
5.0 lg/mL) against B. cereus (MTCC-430). Antibacterial activ-
ity of compounds 10–30 (MIC in lg/mL) is summarized in
Table 2.2.2.2. Antifungal activity
Most of the fungal infections are treatable on a result in min-
imal complications such as redness, itching and discomfort,
though complication may be severe or fatal if left untreated
in certain populations [26]. In immuno-compromised patients,
Candida infections can affect the esophagus with the potential
of becoming systemic, causing more serious condition, a funge-
mia called candidemia. Children, mostly between the ages of
three and nine years of age, can be affected by chronic mouth
fungal infections [27]. Synthesized compounds were evaluated
for their antifungal activity against Candida albicans (MTCC-
3017), Aspergillus niger (MTCC-1344) and Fusarium oxyspora
(MTCC-1755) [28]. The in vitro antifungal activities of the
Table 1 Physical properties of 1,3,4-thiadiazole; triazole-5-thione and 1,3-thiazolan-4-one derivatives of benzimidazole.
Compound Code Molecular Formula Mol. Wt M.P. (C) Rf value % Yield
3 C8H9N3 147.18 205–207 0.56 71.21
4 C9H7N3S 189.24 211–214 0.63 65.94
6 C13H11N3 209.11 208–211 0.71 63.72
7 C14H9N3S 251.31 205–207 0.65 61.49
9 C15H14N6OS 326.09 215–217 0.61 61.46
10 C15H12N6S 308.08 215–217 0.67 65.70
11 C17H13N5O2S 351.08 210–213 0.71 58.73
12 C15H12N6S 308.36 218–221 0.64 60.47
13 C20H16N6OS 388.45 225–227 0.64 58.91
14 C20H14N6S 370.43 222–224 0.66 60.05
15 C22H15N5O2S 413.45 217–219 0.69 59.67
16 C20H14N6S 370.43 228–231 0.64 58.21
18 C17H17N5OS 339.41 240–243 0.59 61.82
19 C17H15N5S 321.41 239–241 0.62 57.94
20 C19H16N4O2S 364.42 244–245 0.68 58.64
21 C17H15N5S 321.41 241–243 0.64 54.92
23 C18H17N5OS 351.43 215–217 0.58 57.38
24 C18H15N5S 333.41 221–223 0.59 60.31
25 C20H16N4O2S 376.43 225–227 0.61 64.39
26 C18H15N5S 333.41 231–233 0.65 58.37
27 C22H19N5OS 401.48 240–242 0.63 61.34
28 C22H17N5S 383.47 238–241 0.65 59.28
29 C24H18N4O2S 426.49 245–247 0.61 60.76
30 C22H17N5S 383.47 241–243 0.64 62.94
Table 2 Antibacterial activity of compounds 10–30 (MIC in lg/mL).
Compounds Microorgan-isms
B. cereus E. faecalis S. aureus E. coli P. aeruginos K. pneumonia
10 15 15 18 20 20 17
11 10 15 17 14 15 15
12 14 12 14 18 14 14
13 15 16 15 16 17 14
14 12 14 15 15 16 16
16 14 13 17 17 17 18
18 12 14 15 15 18 18
19 16 14 17 18 20 21
20 10 15 15 21 25 25
21 7 11 12 14 15 14
23 10 10 12 15 14 16
24 5 7 7 10 10 9
25 7 8 7 8 8 11
26 12 13 13 10 12 14
27 11 10 10 11 12 16
28 8 8 8 10 11 11
29 5 7 8 8 8 11
30 5 9 11 10 10 10
Oﬂoxacine 2 2 3 4 4 5
Metronidazole 3 3 3 3 4 4
S38 K.P. Barot et al.benzimidazole derivatives were characterized against different
fungal organisms. Some of the synthesized compounds N-
((1H-benzo[d] imidazol-2-yl) methyl)-5-benzyl-1,3,4-thia-
diazol-2-amine 19 and 2-((1H-benzo[d] imidazol-2-yl) methyli-
mino)-3-isonicotinoyl thiazolidin-4-one 15 showed potent
antifungal activity (MIC 7.0 lg/mL) against A. niger
(MTCC-1344). Antifungal activity of compounds 10–30
(MIC in lg/mL) is shown in Table 3.2.3. MICs determinations
Minimum inhibitory concentration (MIC) is the lowest concen-
tration of the drug which inhibits growth of the bacteria and
fungi [29]. A pure culture of a single microorganism was grown
in Mueller–Hinton broth. The antimicrobial agents were di-
luted a number of times, 1:1, through a sterile diluent (usually
Mueller Hinton broth). A volume of the standardized inoculum
Table 3 Antifungal activity of compounds 10–30 (MIC in lg/
mL).
Compounds Microorganisms
Candida albicans
(MTCC-3017)
Aspergillus niger
(MTCC-1344)
Fusarium oxyspora
(MTCC-1755)
10 10 10 14
11 13 17 14
12 15 16 17
13 17 17 20
14 20 22 17
15 11 7 14
16 24 21 23
18 14 10 10
19 8 7 8
20 14 12 12
21 17 17 21
23 8 10 12
24 27 22 21
25 22 24 18
26 11 12 11
27 14 15 14
28 21 26 24
29 19 24 24
30 7 10 10
Fluconazole 2 3 3
Design, synthesis and antimicrobial activities S39equal to the volume of the diluted antimicrobial agent was
added to each dilution vessel, bringing the microbial concentra-
tion to approximately 500,000 cells per milliliter, after the anti-
microbial agent was diluted. The inoculated, serially diluted
antimicrobial agent was incubated at an appropriate tempera-
ture for the test organism for a pre-set period, usually 18 h.
After incubation, the series of dilution vessels were observed
for microbial growth. It was usually indicated by turbidity
and/or a pellet of microorganisms in the bottom of the vessel.
The synthesized compounds and referral standard drugs (anti-
microbial agents) were diluted a number of times, 1:1, through
a sterile diluent (usually Mueller Hinton broth) [30,31].
2.4. Structure–activity relationship (SAR)
Structure–activity relationship study suggests that 2-subsituted
benzimidazole and its derivatives are required for potentFigure 1 Structure–activity relationship study of 1,3,4-thiadiazole;
daozle for potent antimicrobial activity.antibacterial and antifungal activities [32]. Position-2 should
be –CH2, –CH2– NH–, CH3–C6H5, –NH–CH3 or CH3–
C6H5–CH3 provides more favorable potent antimicrobial
activity. These substituted benzimidazole derivatives are also
active against other microbial species to resist them. Substitu-
ent position and arrangement of groups and rings are better to
good antimicrobial activities. Resonance with benzimidazole
derivatives provides optimum activity against both Gram-
positive and Gram-negative bacteria. Position-3 should be
1,3,4-thiadiazole; triazole-5-thione or 1,3-thiazolan-4 one
provides potent antibacterial and antifungal activities. But,
1,3-thiazolan-4-one moiety is most favorable for potent anti-
microbial activity due to thiazolan moiety [33]. SAR study also
suggests that all the synthesized lead targeted compounds
include different hydrazide derivatives such as phenylacetic
acid hydrazide, cinnamic acid hydrazide, benzoicacid hydra-
zide and isoniazide. But, phenylacetic acid hydrazide is more
favorable than isoniazide and other types of hydrazide deriva-
tives for the potent antimicrobial activity. Therefore, it sug-
gests that position-1 having 2-subsituted benzimidazole is
required for the potent antibacterial and antifungal activities.
Other suitable groups and rings at the different positions are
mentioned as per their favorability for antimicrobial activity.
The arrangement of groups and rings also affects better to
good activities [34]. Structure–activity relationship (SAR)
study of 1,3,4-thiadiazole; triazole-5-thione and 1,3-thiazo-
lan-4-one derivatives of benzimidazole for potent antimicro-
bial activity is shown in Fig. 1.
3. Experimental section
3.1. General
All the reagents were purchased from Sigma–Aldrich Chemi-
cals (Bangalore, India) and were used without further puriﬁca-
tion. All solvents were distilled and dried using dry sieves as the
usual manner. TLC analysis was carried out on an aluminum
foil pre-coated with silica gel 60 F254 (Sigma–Aldrich, Banga-
lore dealer). Melting points were determined on a Thomas mi-
cro hot stage apparatus and are uncorrected. Infrared spectra
were determined as KBr solid pellets on a Shimadzu model
470 spectrophotometer. Mass spectra were recorded on a JEOL
JMS-600H instrument using electro spray ionization (ESI)triazole-5-thione and 1,3-thiazolan-4-one derivatives of benzimi-
S40 K.P. Barot et al.detector. 1H NMR spectra were recorded using a Jeol Eclipse
400 MHz spectrometer using CDCl3 as NMR solvent and are
reported in ppm down ﬁeld from the residual CDCl3. Elemental
analysis was performed on a Elementar Vario Micro Cube ana-
lyzer and results were within ±0.4% of the predicted values for
all compounds. 13C NMR showed various types of signals at
different ppmwhich were assigned for the different types of car-
bons of all the target compounds. The synthetic routes leading
to the title compounds are summarized in scheme.
3.2. Synthesis
3.2.1. Synthesis of (1H-benzo[d]imidazol-2-yl)methanamine
(3)
o-Phenylenediamine 1 (5.0 g, 11.0 mmol) was dissolved in 20 mL
water under heating with continuous stirring. Conc. HCl
(20 mL) was added with glycine 2 (3.45 g, 8.0 mmol) to the reac-
tion mixture. Resulted reaction mixture was reﬂuxed for 50–
55 min at 70–73 C and reaction was monitored by TLC. After
completion of reaction, reaction mixture was cooled by water
and then neutralized with ammonia solution to precipitate the
product, separated by vacuum ﬁltration and recrystallized with
95% ethanol. Further puriﬁcation was accomplished by column
chromatography to obtain white needle shape crystals of the
product (Mobile Phase: Hexane: Ethyl acetate – 4:6).
3.2.2. Synthesis of 2-(isothiocyanatomethyl)-1H-
benzo[d]imidazole (4)
A suspension of (1H-benzo[d]imidazol-2-yl)methanamine 3
(4.5 g, 10.0 mmol) was dissolved in pyridine (2.69 mL,
7.5 mmol) and iodine (2.62 g, 7.0 mmol) at 0–5 C. It was al-
lowed to stir for 20 min and then carbon disulﬁde (2.58 mL,
5.5 mmol) was added to the above reaction mixture at 0–5 C.
Resulted reaction mixture was allowed to stir for 4 h at 0–5 C
and the reaction was monitored by TLC. After completion of
the reaction, excess CS2 and pyridine were removed by vacuum
distillation to obtain crude product. Further puriﬁcation was
accomplished by column chromatography to obtain buff white
color product (Mobile Phase: Hexane: Ethyl acetate – 5:5).
3.2.3. 4-(1H-benzo[d]imidazol-2-yl)benzenamine (6)
o-phenylenediamine 1 (5.0 g, 10.0 mmol) was dissolved in
20 mL water under heating with continuous stirring. Conc.
HCl (20 mL) and p-amino benzoic acid (PABA) 5 (6.3 g,
11.5 mmol) were added to the above reaction mixture. Re-
sulted reaction mixture was allowed to reﬂux for 50–55 min
at 70–73 C and reaction was monitored by TLC. After com-
pletion of reaction, reaction mixture was cooled by water
and then neutralized with ammonia solution to precipitate
the product, separated by vacuum ﬁltration and recrystallized
with 95.0% ethanol. Further puriﬁcation was accomplished by
column chromatography to obtain white needle shape crystals
of the product. (Mobile Phase: Benzene: Ethyl acetate – 4:1).
3.2.4. 4-(1H-benzo[d]imidazol-2-yl)benzenamine (7)
4-(1H-benzo[d]imidazol-2-yl)benzenamine 6 (4.3 g, 9.5 mmol)
was dissolved in pyridine (2.60 mL, 7.2 mmol) and iodine
(2.60 g, 6.0 mmol) at 0–5 C. It was allowed to stir for
20 min and then carbon disulﬁde (2.45 mL, 5.5 mmol) was
added to the above reaction mixture at 0–5 C. Resulted reac-tion mixture was allowed to stir for 4 h at 0–5 C and the reac-
tion was monitored by TLC. After completion of reaction,
excess CS2 and pyridine were removed by vacuum distillation
to obtain crude product. Further puriﬁcation was accom-
plished by column chromatography to obtain buff white color
product (Mobile Phase: Hexane: Ethyl acetate – 3:7).
3.2.5. 4-((1H-benzo[d]imidazol-2-yl)methyl)-1-
isonicotinoylthiosemicarbazide (9)
2-(isothiocyanatomethyl)-1H-benzo[d]imidazole 4 (3.8 g,
7.5 mmol) was dissolved in water. Isoniazide 8 (1.6 g,
7.0 mmol)) was added into it and allowed to reﬂux with
40 mL ethanol for 3.5 h and reaction was monitored by
TLC. After completion of reaction, reaction mixture was
cooled at 0–5 C and was distilled off to remove ethanol from
it and extracted with ethyl acetate. Organic layer was dried
over sodium sulfate and distilled off to get crude product. Fur-
ther puriﬁcation was accomplished by column chromatogra-
phy to obtain pale yellow color product (Mobile phase:
Hexane : Ethyl acetate– 4:6).
3.2.6. N-((1H-benzo[d]imidazol-2-yl)methyl)-5-(pyridin-4-
yl)-1,3,4-thiadiazol-2-amine (10)
Sulfuric acid (50 %, 15.0 mL, 10.5 mmol) was added drop wise
to 4-((1H-benzo[d]imidazol-2-yl)methyl)-1-isonicotinoylthiose-
micarbazide 9 (2.1 g, 0.0064 mmol). Resulted reaction mixture
was allowed to reﬂux at 75–77 C for 2–2.5 h. After comple-
tion of reaction, reaction mixture was cooled at 0–5 C and ex-
tracted dichloromethane. Organic layer was dried over sodium
sulfate and distilled off to get crude product. Further puriﬁca-
tion was accomplished by column chromatography to obtain
light yellowish color product (Mobile Phase: Hexane: Ethyl
acetate – 4:5).
3.2.7. (Z)-2-((1H-benzo[d]imidazol-2-yl)methylimino)-3-
isonicotinoylthiazolidin-4-one (11)
4-((1H-benzo[d]imidazol-2-yl)methyl)-1-isonicotinoylthiose-
micarbazide 9 (2.0 g, 10.0 mmol) was dissolved in chloroacetyl-
chloride (30.0 mL, 7.5 mmol). Resulted reaction mixture was
allowed to reﬂux within chloroform (90.0 mL) for 6.0 h and
the reaction was monitored by TLC. After completion of reac-
tion, reaction mixture was cooled at 0–5 C and was distilled
off to remove chloroform from it and extracted with ethyl ace-
tate. Organic layer was dried over sodium sulfate and distilled
off to get crude product. Further puriﬁcation was accom-
plished by column chromatography to obtain yellowish brown
color product (Mobile Phase: Hexane: Ethyl acetate – 4:6).
3.2.8. 4-((1H-benzo[d]imidazol-2-yl)methyl)-5-(pyridin-4-yl)-
2H-1,2,4-triazole-3(4H)-thione (12)
4-((1H-benzo[d]imidazol-2-yl)methyl)-1-isonicotinoylthiose-
micarbazide 9 (2.0 g, 12.5 mmol) was dissolved in 2M NaOH
(30.0 mL) solution and allowed to reﬂux at 75–78 C for
6.0 h and the reaction was monitored by TLC. After comple-
tion of reaction, reaction mixture was cooled at 0–5 C and
acidiﬁed with HCl (20.0 mL) and extracted with ethyl acetate.
Organic layer was dried over sodium sulfate and distilled off to
get crude product. Further puriﬁcation was accomplished by
column chromatography to obtained buff white color product
(Mobile Phase: Hexane: Ethyl acetate – 5:5).
Design, synthesis and antimicrobial activities S413.2.9. N-((1H-benzo[d]imidazol-2-yl)methyl)-5-(pyridin-4-
yl)-1,3,4-thiadiazol-2-amine (10)
Yield 65.70% mp 215–217 C. IR (KBr) c (cm1): 3121–2963
(Ar–CH), 1625.32 (C‚N), 1517.56 (C‚C), 3380.98 (N–H),
2918.10 (3o amine), 1517.87 (–CH2), 1286.93 (C–N).
1H
NMR (CDCl3, d ppm): 6.85 (d, 1H, J= 7.8 Hz), 6.36 (d,
1H, J= 2.4 Hz), 6.34 (s, 1H), 6.27 (d, 1H, J= 9.9 Hz), 5.48
(d, 1H, J= 9.9 Hz), 1.43 (s, 6H). 13C NMR (CDCl3) d:
175.25, 164.30, 148.91, 143.4, 141.23, 138.40, 123.50, 121.30,
115.26, 43.40. Anal. Calcd for C15H12N6S: C, 58.43; H, 3.92;
N, 27.25; S, 10.40; Found: C, 57.56; H, 2.97; N, 26.46; S,
11.24. MS (ESI, m/z): 309.1 (M++1).
3.2.10. (Z)-2-((1H-benzo[d]imidazol-2-yl)methylimino)-3-
isonicotinoylthiazolidin-4-one (11)
Yield 58.73% mp 210–213 C. IR (KBr) c (cm1): 3120–2943
(Ar–CH), 1635.92 (C‚N), 1523.38 (C‚C), 1687.0 (C‚O),
3377.84 (N–H), 2920.15 (3o amine), 1514.89 (–CH2), 1289.60
(C–N). 1H NMR (CDCl3, d ppm): 8.43 (d, J= 5.1 Hz, 2H),
7.21 (d, J= 4.3 Hz, 2H), 7.25 (dd, J= 8.7 Hz, 2H), 7.18
(dd, J= 8.2 Hz, 2H), 7.0 (s, 1H), 5.0 (s, 1H), 4.71 (s, 2H).
13C NMR (CDCl3) d: 171.12, 170.23, 163.58, 149.25, 140.92,
138.52, 122.80, 122.5, 115.31, 30.12. Anal. Calcd for
C17H13N5O2S: C, 58.11; H, 3.73; N, 19.93; O, 9.11; S, 9.13;
Found: C, 57.32; H, 2.76; N, 20.37; O, 8.64; S, 8.17. MS
(ESI, m/z): 352.0 (M++1).
3.2.11. 4-((1H-benzo[d]imidazol-2-yl)methyl)-5-(pyridin-4-
yl)-2H-1,2,4-triazole-3(4H)-thione (12)
Yield 60.47% mp 218–221 C. IR (KBr) c (cm1): 3150–2960
(Ar–CH), 1637.11 (C‚N), 1525.13 (C‚C), 1685.12 (C‚O),
3370.21 (N–H), 2925.12 (3o amine), 1515.12 (CH2), 1290.11 (C–
N). 1H NMR (CDCl3, d ppm): 8.66 (d, J= 5.2 Hz, 2H), 7.98
(d, J= 5.2 Hz, 2H), 7.59 (dd, J= 8.7 Hz, 2H), 7.22 (dd,
J= 8.7 Hz, 2H), 7.0 (s, 1H), 5.0 (s, 1H), 4.71 (s, 2H). 13C
NMR (CDCl3) d: 186.12, 155.10, 149.50, 141.23, 138.90,
136.70, 123.20, 121.12, 115.3, 48.71. Anal. Calcd for
C15H12N6S: C, 58.43; H, 3.92; N, 27.25; S, 10.40; Found: C,
57.46; H, 2.31; N, 28.73; S, 11.27.MS (ESI,m/z): 309.4 (M++1).
3.2.12. N-(4-(1H-benzo[d]imidazol-2-yl)phenyl)-5-(pyridin-4-
yl)-1,3,4-thiadiazol-2-amine (14)
Yield 60.05% mp 222–224 C. IR (KBr) c (cm1): 3118–2911
(Ar–CH), 1620.53 (C‚N), 1510.25 (C‚C), 3381.21 (N–H),
2917.15 (3o amine), 1518.11 (–CH2), 1287 (C–N).
1H NMR
(CDCl3, d ppm): 8.59 (d, J= 7.1 Hz, 2H), 8.5 (d, J= 7.0 Hz,
2H), 7.40 (dd, J= 8.3 Hz, 2H), 7.25 (dd, J= 8.4 Hz, 2H),
7.1 (s, 1H), 5.0 (s, 1H), 5.3 (s, 2H). 13C NMR (CDCl3) d:
175.10, 152.7, 149.11, 143.25, 138.90, 128.31, 122.80, 120.81,
116.23, 115.23, 90.56. Anal. Calcd for C20H14N6S: C, 64.85;
H, 3.81; N, 22.69; S, 8.66; Found: C, 63.87; H, 2.74; N,
24.27; S, 7.06. MS (ESI, m/z): 371.6 (M++1).
3.2.13. (Z)-2-(4-(1H-benzo[d]imidazol-2-yl)phenylimino)-3-
isonicotinoylthiazolidin-4-one (15)
Yield 59.67% mp 217–219 C. IR (KBr) c (cm1): 3115–2920
(Ar–CH), 1641.25 (C‚N), 1521.25 (C‚C), 1678.65 (C‚O),
3376.25 (N–H), 2925.36 (3o amine), 1516.37 (CH2), 1290.10
(C–N). 1H NMR (CDCl3, d ppm): 8.64 (d, J= 5.3 Hz, 2H),
7.25 (d, J= 4.6 Hz, 2H), 7.20 (dd, J= 8.4 Hz, 2H), 7.15(dd, J= 8.4 Hz, 2H), 7.1 (s, 1H), 5.3 (s, 1H), 4.75 (s, 2H).
13C NMR (CDCl3) d: 175.23, 152.63, 149.36, 143.75, 128.65,
121.53, 121.41, 116.80, 115.26. Anal. Calcd for C22H15N5O2S:
C, 63.91; H, 3.66; N, 16.94; O, 7.74; S, 7.76; Found:C, 62.34;
H, 2.45; N, 15.64; O, 6.47; S, 6.78. MS (ESI, m/z): 414.2
(M++1).
3.2.14. 4-(4-(1H-benzo[d]imidazol-2-yl)phenyl)-5-(pyridin-4-
yl)-2H-1,2,4-triazole-3(4H)-thione (16)
Yield 58.21% mp 228–231 C. IR (KBr) c (cm1): 3133–2942
(Ar–CH), 1640.25 (C‚N), 1521.28 (C‚C), 1686.82 (C‚O),
3372.25 (N–H), 2926.89 (3o amine), 1516.95 (–CH2), 1292.10
(C–N). 1H NMR (CDCl3, d ppm): 8.60 (d, J= 5.0 Hz, 2H),
7.90 (d, J= 5.12 Hz, 2H), 7.51 (dd, J= 8.0 Hz, 2H), 7.0
(dd, J= 8.1 Hz, 2H), 7.5 (s, 1H), 5.0 (s, 1H), 4.68 (s, 2H);
13C NMR (CDCl3) d: 175.12, 152.63, 149.80, 143.10, 141.50,
138.91, 135.76, 128.50, 123.64, 122.0, 116.80, 115.41. Anal.
Calcd for C20H14N6S: C, 64.85; H, 3.81; N, 22.69; S, 8.66;
Found: C, 63.45; H, 2.72; N, 21.64; S, 7.16. MS (ESI, m/z):
371.5 (M++1).
3.2.15. N-((1H-benzo[d]imidazol-2-yl)methyl)-5-benzyl-1,3,4-
thiadiazol-2-amine (19)
Yield 57.94% mp 239–241 C. IR (KBr) c (cm1): 3120–2921
(Ar–CH), 1621.39 (C‚N), 1512.58 (C‚C), 3382.40 (N–H),
2918 (3o amine), 1518.87 (–CH2), 1288.12 (C–N).
1H NMR
(CDCl3, d ppm): 8.67 (d, J= 7.14 Hz, 2H), 8.20 (d,
J= 7.5 Hz, 2H), 7.42 (dd, J= 8.3 Hz, 2H), 7.32 (dd,
J= 8.35 Hz, 2H), 7.0 (s, 1H), 5.4 (s, 1H), 5.15 (s, 2H). 13C
NMR (CDCl3) d: 175.13, 152.48, 149.80, 143.74, 143.15,
141.54, 137.18, 128.30, 122.94, 116.58, 115.46. Anal. Calcd
for C17H15N5S: C, 63.53; H, 4.70; N, 21.79; S, 9.98; Found:
C, 62.25; H, 3.47; N, 20.64; S, 8.37. MS (ESI, m/z): 322.0
(M++1).
3.2.16. (Z)-2-((1H-benzo[d]imidazol-2-yl)methylimino)-3-(2-
phenylacetyl)thiazolidin-4-one (20)
Yield 58.64% mp 244–246 C. IR (KBr) c (cm1): 3100–2958
(Ar–CH), 1638.10 (C‚N), 1521.86 (C‚C), 1686.90 (C‚O),
3378.42 (N–H), 2921.14 (3o amine), 1515.85 (–CH2), 1290
(C–N). 1H NMR (CDCl3, d ppm): 8.45 (d, J= 5.8 Hz, 2H),
7.2 (d, J= 4.0 Hz, 2H), 7.21 (dd, J= 8.2 Hz, 2H), 7.2 (dd,
J= 8.4 Hz, 2H), 7.4 (s, 1H), 5.2 (s, 1H), 4.77 (s, 2H). 13C
NMR (CDCl3) d: 171.24, 152.9, 152.7, 149.90, 143.65,
143.15, 138.76, 128.54, 128.31, 123.6, 121.48, 116.80, 115.30,
43.90; Anal. Calcd for C19H16N4O2S: C, 62.62; H, 4.43; N,
15.37; O, 8.78; S, 8.80; Found: C, 61.45; H, 3.46; N, 16.85;
O, 7.67; S, 7.78. MS (ESI, m/z): 365.4 (M++1).
3.2.17. 4-((1H-benzo[d]imidazol-2-yl)methyl)-5-benzyl-2H-
1,2,4-triazole-3(4H)-thione (21)
Yield 54.92% mp 241–243 C. IR (KBr) c (cm1): 3154–2930
(Ar–CH), 1638.45 (C‚N), 1526.28 (C‚C), 1686.10 (C‚O),
3371.12 (N–H), 2924.89 (3o amine), 1516.17 (–CH2), 1291.17
(C–N). 1H NMR (CDCl3, d ppm): 8.61 (d, J= 5.4 Hz, 2H),
7.41 (d, J= 5.4 Hz, 2H), 7.51 (dd, J= 8.8 Hz, 2H), 7.20
(dd, J= 8.2 Hz, 2H), 7.2 (s, 1H), 5.2 (s, 1H), 4.70 (s, 2H).
13C NMR (CDCl3) d: 152.7, 141.85, 137.90, 135.78, 128.5,
123.64, 122.9, 121.4, 115.4; Anal. Calcd for C17H15N5S: C,
63.53; H, 4.70; N, 21.79; S, 9.98; Found: C, 62.35; H, 3.56;
N, 22.65; S, 8.76. MS (ESI, m/z): 322.0 (M++1).
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1,3,4-thiadiazol-2-amine (24)
Yield 60.31% mp 221–223 C. IR (KBr) c (cm1): 3123–2946
(Ar–CH), 1621.52 (C‚N), 1513.10 (C‚C), 3386.79 (N–H),
2917.89 (3o amine), 1519 (–CH2), 1289 (C–N).
1H NMR
(CDCl3, d ppm): 8.66 (d, J= 7.2 Hz, 2H), 8.23 (d,
J= 7.6 Hz, 2H), 7.5 (dd, J= 8.2 Hz, 2H), 7.45 (dd,
J= 8.48 Hz, 2H), 7.2 (s, 1H), 5.1 (s, 1H), 5.2 (s, 2H). 13C
NMR (CDCl3) d: 164.2, 141.50, 138.90, 135.20, 133.4, 128.7,
128.5, 126.4, 123.10, 115.30, 43.4. Anal. Calcd for C18H15N5S:
C, 64.84; H, 4.53; N, 21.01; S, 9.62; Found: C, 65.82; H, 3.76;
N, 22.34; S, 10.75. MS (ESI, m/z): 334.6 (M++1).
3.2.19. (Z)-2-((1H-benzo[d]imidazol-2-yl)methylimino)-3-
cinnamoylthiazolidin-4-one (25)
Yield 64.39% mp 225–227 C. IR (KBr) c (cm1): 3120–2940
(Ar–CH), 1622.12 (C‚N), 1517 (C‚C), 1686.11 (C‚O),
3380.12 (N–H), 2919.25 (3o amine), 1517.10 (–CH2), 1286.15
(C–N). 1H NMR (CDCl3, d ppm): 8.51 (d, J= 5.1 Hz, 2H),
7.98 (d, J= 5.1 Hz, 2H), 7.51 (dd, J= 8.4 Hz, 2H), 7.19
(dd, J= 8.7 Hz, 2H), 7.0 (s, 1H), 5.0 (s, 1H), 4.71 (s, 2H).
13C NMR (CDCl3) d: 171.10, 166.3, 162.80, 144.12, 141.50,
137.90, 135.20, 128.7, 128.0, 126.41, 122.90, 115.41, 30.1. Anal.
Calcd for C20H16N4O2S: C, 63.81; H, 4.28; N, 14.88; O, 8.50;
S, 8.52; Found: C, 64.37; H, 5.84; N, 15.87; O, 9.30; S, 4.91.
MS (ESI, m/z): 377.4 (M++1).
3.2.20. (E)-4-((1H-benzo[d]imidazol-2-yl)methyl)-5-styryl-
2H-1,2,4-triazole-3(4H)-thione (26)
Yield 58.37% mp 231–233 C. IR (KBr) c (cm1): 3122–2964
(Ar–CH), 1623.25 (C‚N), 1517 (C‚C), 1686.18 (C‚O),
3380.96 (N-H), 2919.89 (3o amine), 1518.17 (–CH2), 1287.46
(C–N). 1H NMR (CDCl3, d ppm): 8.67 (d, J= 5.3 Hz, 2H),
7.53 (d, J= 5.4 Hz, 2H), 7.50 (dd, J= 8.1 Hz, 2H), 7.18 (dd,
J= 8.1 Hz, 2H), 7.8 (s, 1H), 5.4 (s, 1H), 4.76 (s, 2H). 13C
NMR (CDCl3) d: 184.28, 162.8, 155.41, 141.54, 139.48,
138.48, 135.24, 128.7, 126.47, 49.2. Anal. Calcd for
C18H15N5S: C, 64.84; H, 4.53; N, 21.01; S, 9.62; Found: C,
63.28; H, 3.78; N, 22.37; S, 8.67.MS (ESI,m/z): 334.2 (M++1).
3.2.21. N-(4-(1H-benzo[d]imidazol-2-yl)phenyl)-5-benzyl-
1,3,4-thiadiazol-2-amine (28)
Yield 59.21% mp 238–241 C. IR (KBr) c (cm-1): 3120–2962
(Ar–CH), 1622.63 (C‚N), 1517.94 (C‚C), 3380.73 (N–H),
2918.97 (3o amine), 1517.84 (–CH2), 1287.46 (C–N).
1H NMR
(CDCl3, d ppm): 8.64 (d, J= 5.3 Hz, 2H), 7.91 (d, J= 5.2 Hz,
2H), 7.51 (dd, J= 8.7 Hz, 2H), 7.20 (dd, J= 8.4 Hz, 2H), 7.0
(s, 1H), 5.0 (s, 1H), 5.3 (s, 2H). 13C NMR (CDCl3) d: 184.23,
162.84, 155.42, 141.23, 139.16, 135.17, 138.45, 128.41, 126.12,
123.14, 122.17, 118.71, 49.21. Anal. Calcd for C22H17N5S: C,
68.91; H, 4.47; N, 18.26; S, 8.36; Found: C, 67.91; H, 3.64; N,
17.34; S, 7.91. MS (ESI, m/z): 384.1 (M++1).
3.2.22. (Z)-2-(4-(1H-benzo[d]imidazol-2-yl)phenylimino)-3-
(2-phenylacetyl)thiazolidin-4-one (29)
Yield 60.76% mp 245–247 C. IR (KBr) c (cm-1): 3120–2962
(Ar–CH), 1623.76 (C‚N), 1517.43 (C‚C), 1685.98 (C‚O),
3381.12 (N–H), 2919.0 (3o amine), 1517.11 (–CH2), 1287.11
(C–N). 1H NMR (CDCl3, d ppm): 8.60 (d, J= 5.1 Hz, 2H),
7.50 (d, J= 5.1 Hz, 2H), 5.5 (s, 1H), 7.25 (dd, J= 8.6 Hz,2H), 7.21 (dd, J= 8.7 Hz, 2H), 7.1 (s, 1H), 5.1 (s, 1H), 4.71
(s, 2H). 13C NMR (CDCl3) d: 190.10, 155.12, 141.21, 137.91,
135.20, 128.70, 128.0, 126.41, 123.21, 118.12, 115.30, 28.31,
16.10; Anal. Calcd for C24H18N4O2S: C, 67.59; H, 4.25; N,
13.14; O, 7.50; S, 7.52; Found: C, 68.38; H, 3.5; N, 14.78; O,
6.45; S, 6.03. MS (ESI, m/z): 427.0 (M++1).
3.2.23. 4-(4-(1H-benzo[d]imidazol-2-yl)phenyl)-5-benzyl-2H-
1,2,4-triazole-3(4H)-thione (30)
Yield 62.94% mp 241–243 C. IR (KBr) c (cm-1): 3121–2962
(Ar–CH), 1623.10 (C‚N), 1518.10 (C‚C), 1686.14 (C‚O),
3381.23 (N–H), 2918.19 (3o amine), 1517.89 (–CH2), 1286.91
(C–N). 1H NMR (CDCl3, d ppm): 8.66 (d, J= 5.2 Hz, 2H),
7.95 (d, J= 5.21 Hz, 2H), 7.59 (dd, J= 8.7 Hz, 2H), 7.22
(dd, J= 8.1 Hz, 2H), 7.1 (s, 1H), 5.0 (s, 1H), 4.70 (s, 2H).
13C NMR (CDCl3) d: 189.98, 162.14, 154.82, 141.26, 138.14,
135.21, 128.41, 126.78, 123.14, 122.90, 49.57, 16.18. Anal.
Calcd for C22H17N5S: C, 68.91; H, 4.47; N, 18.26; S, 8.36;
Found: C, 67.82; H, 3.65; N, 17.64; S, 7.64. MS (ESI, m/z):
384.1 (M++1).
4. Conclusion
Substituted benzimidazoles containing 1,3,4-thiadiazole;
1,2,4-triazole-5-thione and 1,3-thiazolan-4-one derivatives
were synthesized by nucleophilic substitution reaction of
2-substituted-1[H] benzimidazole. The pharmacological
study was undertaken to evaluate the effects of substituent
on the antibacterial and antifungal activities. Compounds
24, 29 and 30 have shown good antibacterial activity to-
ward Gram-positive and Gram-negative bacteria. Com-
pounds 15 and 19 have shown good to moderate
antifungal activity. It is concluded that as the number of
carbon atom increases in side chain at 2-position of benz-
imidazole, it causes an increase in the activity against S.
aureus, B. subtilis and C. albicans which supports the che-
motherapeutic activity.Acknowledgments
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